Phase 2 Single-Arm, Open-Label Study of Nivolumab in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL)
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 17 Sep 2019
Price : $35 *
At a glance
- Drugs Nivolumab (Primary)
- Indications Anaplastic large cell lymphoma; Mycosis fungoides; Peripheral T-cell lymphoma; T-cell leukaemia
- Focus Therapeutic Use
- 13 Sep 2019 Status changed from recruiting to active, no longer recruiting.
- 12 Aug 2019 Planned primary completion date changed from 15 Mar 2022 to 30 Sep 2021.
- 31 Aug 2018 Biomarkers information updated